Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancer

2014 ◽  
Vol 81 (2) ◽  
pp. 271-275 ◽  
Author(s):  
Stephanie Smooke-Praw ◽  
Kevin Ro ◽  
Olga Levin ◽  
Philip H. G. Ituarte ◽  
Avital Harari ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Disease Status ◽  
Papillary Thyroid ◽  
Thyroglobulin Antibody ◽  
Antibody Levels

scholarly journals Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer

Medicine ◽  
2018 ◽  
Vol 97 (36) ◽  
pp. e12242 ◽  
Author(s):  
Ning Li ◽  
Chunmei Zhang ◽  
Zhaowei Meng ◽  
Ke Xu ◽  
Xianghui He ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factor ◽  
Papillary Thyroid Cancer ◽  
Disease Status ◽  
Papillary Thyroid

scholarly journals Evaluation of Thyroglobulin Antibody Normalization in Papillary Thyroid Cancer Patients Receiving High-Dose I-131 Therapy

2021 ◽  
Author(s):  
Sang Hyun Hwang ◽  
KwanHyeong Jo ◽  
Chun Goo Kang ◽  
Jiyoung Wang ◽  
Hojin Cho ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Papillary Thyroid Cancer ◽  
Multivariable Analysis ◽  
Reduction Rate ◽  
Whole Body ◽  
High Dose ◽  
Papillary Thyroid ◽  
Thyroglobulin Antibody ◽  
Ablation Success

Abstract Purpose: Thyroglobulin antibody (TgAb) elevation after I-131 ablation may be difficult to evaluate in cases of recurrence, especially in high-risk patients. This study aimed to evaluate factors contributing to TgAb normalization in papillary thyroid cancer patients receiving high-dose I-131 therapy. Methods: From September 2009 to June 2012, 98 papillary thyroid cancer patients treated with 150 mCi radioactive iodine (RAI) were retrospectively enrolled. Early (3 day) and Delayed (7 day) post-RAI neck counts and reduction ratios were measured and correlated with clinical and pathologic findings. Patients with normal neck ultrasound and undetectable level of serum thyroglobulin (<0.1 ng/mL) and TgAb (<10 IU/mL) were defined as having successful ablation.Results: Thirty-five patients (35.7%) had thyroiditis and 28 (28.6%) achieved ablation success. The thyroiditis group had lower neck counts in both Early and Delayed whole-body scans (WBS), and higher reduction rates than the thyroiditis-absent group. In the ablation success group, Early and Delayed neck counts were significantly higher and the reduction rate of RAI was lower than those in the ablation failure group (p < 0.05). In multivariable analysis, Delayed neck count was the only significant factor for predicting ablation failure (odds ratio = 54.37, 95% confidence interval = 1.33-14.32; p = 0.015).Conclusion: I-131 uptake in the remnant thyroid gland and thyroiditis are factors that indicate TgAb normalization and ablation success in thyroid cancer patients receiving high-dose I-131 therapy.

scholarly journals Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Ben Ma ◽  
Tian Liao ◽  
Duo Wen ◽  
Chuanpeng Dong ◽  
Li Zhou ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Signaling Pathway ◽  
Papillary Thyroid Cancer ◽  
Enrichment Analysis ◽  
Disease Status ◽  
Gene Set Enrichment Analysis ◽  
The Cancer Genome Atlas ◽  
Advanced Tumor Stage ◽  
Papillary Thyroid ◽  
Advanced Tumor

Abstract A number of long non-coding RNAs (lncRNAs) have been found to play critical roles in oncogenesis and tumor progression. We aimed to investigate whether lncRNAs could act as prognostic biomarkers for papillary thyroid cancer (PTC) that may assist us in evaluating disease status and prognosis for patients. We found 220 lncRNAs with expression alteration from the annotated 2773 lncRNAs approved by the HUGO gene nomenclature committee in The Cancer Genome Atlas (TCGA) dataset, of which FAM41C, CTBP1-AS2, LINC00271, HAR1A, LINC00310 and HAS2-AS1 were associated with recurrence. After adjusting classical clinicopathogical factors and BRAF V600E mutation, LINC00271 was found to be an independent risk factor for extrathyroidal extension, lymph node metastasis, advanced tumor stage III/IV and recurrence in multivariate analyses. Additionally, LINC00271 expression was significantly downregulated in PTCs versus adjacent normal tissues (P < 0.001). The Gene Set Enrichment Analysis (GSEA) revealed that genes associated with cell adhesion molecules, cell cycle, P53 signaling pathway and JAK/STAT signaling pathway were remarkably enriched in lower-LINC00271 versus higher-LINC00271 tumors. In conclusion, LINC00271 was identified as a possible suppressor gene in PTC in our study, and it may serve as a potential predictor of poor prognoses in PTC.

scholarly journals Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?

2021 ◽  
Vol 10 (11) ◽  
pp. 2438
Author(s):  
Aleksandra Gajowiec ◽  
Anna Chromik ◽  
Kinga Furga ◽  
Alicja Skuza ◽  
Danuta Gąsior-Perczak ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Predictive Factor ◽  
Disease Status ◽  
Initial Therapy ◽  
Clinicopathological Features ◽  
Response To Therapy ◽  
Papillary Thyroid ◽  
Male Sex

Identifying risk factors is crucial for predicting papillary thyroid cancer (PTC) with severe course, which causes a clinical problem. The purpose of this study was to assess whether male sex can be such a predictive factor and to verify whether including it as a predictive factor of high initial risk of recurrence/persistence would help to enhance the value of the American Thyroid Association initial risk stratification system (ATA). We retrospectively analyzed 1547 PTC patients (1358 females and 189 males), treated from 1986 to 2018. The relationship between sex and clinicopathological features, response to therapy, and disease status was assessed. Men with PTC showed some adverse clinicopathological features more often than women, including angioinvasion, lymph node metastases, and tumor size > 40 mm. There were sex-related disparities with respect to response to initial therapy and final follow-up. Male sex is associated with some unfavorable clinicopathological features of PTC, which may affect response to initial therapy or final disease status. In our study, modification of the ATA system by including male sex as a risk factor does not enhance its value. Thus, further studies are needed to assess whether males require treatment modalities or oncological follow-up protocols that are different from those of females.

scholarly journals Recurrence of papillary thyroid cancer suspected by high anti-thyroglobulin antibody levels and detection of peripheral blood thyroglobulin mRNA

2008 ◽  
Vol 52 (8) ◽  
pp. 1321-1325 ◽  
Author(s):  
Sabrina Mendes Coelho ◽  
Alexandru Buescu ◽  
Rossana Corbo ◽  
Denise P. Carvalho ◽  
Mário Vaisman
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Peripheral Blood ◽  
Cancer Recurrence ◽  
Papillary Thyroid ◽  
Positron Emission ◽  
Thyroglobulin Antibody ◽  
Increased Risk ◽  
Risk Of Cancer

The amplification of thyroglobulin (TG) mRNA in peripheral blood of patients with thyroid cancer has been studied for almost one decade, but its real contribution for diagnosis of cancer relapse has not yet been established. In the present paper we report the case of a patient with papillary thyroid cancer with undetectable stimulated serum thyrogobulin levels after thyroid ablation. Follow-up showed the presence of high titers of anti-thyroglobulin antibodies and the presence of TG mRNA in a peripheral blood sample, while cervical ultrasound and thorax and cervical computerized tomography were negative. Reinvestigation confirmed lymph node metastases. Anti-TG antibodies progressively decreased after surgery for metastatic lymph nodes resection followed by radioiodine therapy. Although our recent findings show that patients with positive TG mRNA do not have increased risk of cancer recurrence after 24 months of follow-up, the presence of TG mRNA along with high anti-TG antibodies were important indicators that determined further extensive investigation of tumour relapse in this patient, since positron emission tomography scan was not available at our Institution. A methodological standardization that can distinguish specific from non-specific TG mRNA amplification might be of great interest for the follow-up of differentiated thyroid cancer, especially in patients with high levels of anti-TG antibodies.

Sign in / Sign up

Export Citation Format

Share Document